Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Debt (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Non-Current Debt for 4 consecutive years, with $110.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 1.06% to $110.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.1 million through Dec 2025, up 1.06% year-over-year, with the annual reading at $110.1 million for FY2025, 1.06% up from the prior year.
  • Non-Current Debt for Q4 2025 was $110.1 million at Centessa Pharmaceuticals, roughly flat from $109.8 million in the prior quarter.
  • The five-year high for Non-Current Debt was $110.1 million in Q4 2025, with the low at $67.4 million in Q2 2022.
  • Average Non-Current Debt over 4 years is $84.5 million, with a median of $75.7 million recorded in 2023.
  • The sharpest move saw Non-Current Debt decreased 4.28% in 2023, then skyrocketed 45.07% in 2025.
  • Over 4 years, Non-Current Debt stood at $69.8 million in 2022, then rose by 8.45% to $75.7 million in 2023, then soared by 43.91% to $108.9 million in 2024, then rose by 1.06% to $110.1 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $110.1 million, $109.8 million, and $109.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.